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AbsTrACT
background Deep brain stimulation (DBs) can be an 
effective therapy for tics and comorbidities in select cases 
of severe, treatment-refractory Tourette syndrome (Ts). 
clinical responses remain variable across patients, which 
may be attributed to differences in the location of the 
neuroanatomical regions being stimulated. We evaluated 
active contact locations and regions of stimulation across 
a large cohort of patients with Ts in an effort to guide 
future targeting.
Methods We collected retrospective clinical data and 
imaging from 13 international sites on 123 patients. We 
assessed the effects of DBs over time in 110 patients 
who were implanted in the centromedial (cM) thalamus 
(n=51), globus pallidus internus (Gpi) (n=47), nucleus 
accumbens/anterior limb of the internal capsule (n=4) or 
a combination of targets (n=8). contact locations (n=70 
patients) and volumes of tissue activated (n=63 patients) 
were coregistered to create probabilistic stimulation 
atlases.
results Tics and obsessive–compulsive behaviour 
(OcB) significantly improved over time (p<0.01), and 
there were no significant differences across brain 
targets (p>0.05). The median time was 13 months to 
reach a 40% improvement in tics, and there were no 
significant differences across targets (p=0.84), presence 
of OcB (p=0.09) or age at implantation (p=0.08). 
active contacts were generally clustered near the 
target nuclei, with some variability that may reflect 
differences in targeting protocols, lead models and 
contact configurations. There were regions within and 
surrounding Gpi and cM thalamus that improved tics for 
some patients but were ineffective for others. Regions 
within, superior or medial to Gpi were associated with 
a greater improvement in OcB than regions inferior to 
Gpi.
Conclusion The results collectively indicate that DBs 
may improve tics and OcB, the effects may develop over 
several months, and stimulation locations relative to 
structural anatomy alone may not predict response. This 
study was the first to visualise and evaluate the regions 
of stimulation across a large cohort of patients with Ts 
to generate new hypotheses about potential targets for 
improving tics and comorbidities.
INTroduCTIoN
Tourette syndrome (TS) is a neurodevelopmental 
disorder characterised by chronic tics, which are 
spontaneous involuntary movements and vocalisa-
tions.1 TS symptoms typically present at 5–7 years 
of age, and symptoms can be detrimental to social, 
emotional, academic and professional develop-
ment.2 3 An estimated 85.7% of patients with TS 
are diagnosed with one or more comorbid neuro-
psychiatric disorders, such as obsessive–compul-
sive behaviour or disorder (OCB/OCD), attention 
deficit hyperactivity disorder, depression and 
anxiety.4 5 The underlying pathophysiology of TS 
is unclear, but it is thought that aberrant neural 
activity disrupts normal corticostriatal-thalamocor-
tical (CSTC) network function, thereby reducing 
the inhibition of somatosensory urges and move-
ments.6–10 Cognitive behavioural therapies and 
pharmacological interventions are generally the first 
treatment approach and are effective in managing 
TS symptoms in most patients.11–14 A small propor-
tion of patients experience severe, disabling tics 
that do not respond to conventional treatment and 
may be eligible for surgical interventions, such as 
deep brain stimulation (DBS).15 16 DBS has been 
performed in over 150 patients with TS worldwide 
since the first case was reported in 1999.17 18 Several 
open-label trials and a few randomised controlled 
trials collectively indicate that DBS is potentially 
effective in improving tics and comorbidities in 
select patients with severe, treatment-refractory 
symptoms.19–40
Several nuclei connected within the CSTC 
network have been explored as potential targets 
for TS DBS. Modulation of the CSTC network 
with DBS aims to restore normal function and 
improve TS and comorbidities. Nine different brain 
areas have been targeted thus far, including four 
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located in the centromedial (CM) thalamus: the centromedian 
nucleus-parafascicular complex-substantia periventricularis-ven-
tro-oralis internus (CMn-Pf-Spv-Voi) intersection,19 35 41 42 2 mm 
anterior to the CMn-Pf-Spv-Voi region,36 37 CMn,20 38 and the 
ventral anterior/ventrolateral motor regions of the thalamus.33 
Other targets include the anteromedial globus pallidus internus 
(amGPi), the posteroventral GPi (pvGPi) and the globus pallidus 
externus (GPe).21–23 29 37 39 40 43–46 The nucleus accumbens and the 
anterior limb of the internal capsule (NA/ALIC) were first estab-
lished as targets for the treatment of OCD but have also been 
used as targets for DBS in patients with TS.37 47–49 Finally, one 
patient suffering from tics and Parkinson’s disease was reported 
to improve following DBS of the subthalamic nucleus.50
The optimal DBS target for reducing tics and comorbidities in 
patients with TS is a long-standing debate in the field. Previous 
studies have suggested that improvement in TS severity did not 
significantly differ across amGPi, pvGPi, GPe and regions of the 
CM thalamus.18 20 38 51 However, an important distinction to 
make is that in each patient, the reported general target region or 
anatomical coordinates are not necessarily the same as the actual 
stimulation target. Rather, the stimulation target for each patient 
is formed by the unique combination of the DBS electrode place-
ment (as identified in postoperative imaging), the parameters of 
the applied stimulation (active contact(s), frequency, voltage and 
pulse width) and the spatiotemporal effects of the stimulation on 
the surrounding neural structures.52–54 There has not yet been 
a systematic comparison of stimulation targets across a cohort 
of TS DBS patients in a common neuroanatomical space. As a 
result, it is unknown how much variability there is in the stimu-
lation targets across patients with TS who have been implanted 
with DBS or if there are specific neuroanatomical regions that 
most effectively improve TS or its associated comorbidities. 
Analyses of the electrode placement and regions of stimulation 
are important for understanding which brain regions either 
maximise the benefit or produce undesired effects during DBS 
for TS in order to guide future targeting approaches.
A potential approach to identify anatomical regions that may 
predict the effects of DBS in patients with TS is to coregister 
patient-specific electrode locations, computational models of the 
volume of tissue activated (VTA) and associated clinical outcome 
scores into a common neuroanatomical space to create proba-
bilistic stimulation atlases (PSAs).52 55 PSAs have been used to 
identify anatomical regions that may predict the therapeutic 
response or side effects during DBS for the treatment of Parkin-
son’s disease, essential tremor, epilepsy and other disorders.55–60 
These methods require high-quality preoperative and postoper-
ative imaging, stimulation settings, and pre-DBS and post-DBS 
clinical outcomes data for each patient. Additionally, curating a 
retrospective data set for PSA analyses requires careful processing 
and integration of heterogeneous data often from multiple clinic 
sites, which has not yet been undertaken for a large cohort of 
patients with TS receiving DBS therapy. Implementing these 
approaches would be an important step towards generating new 
hypotheses about how the current targeting methods can be 
improved in order to produce the best therapeutic outcomes in 
TS DBS patients.
The goal of this study was to create PSAs in order characterise 
how DBS has been applied in patients with TS so far and to 
investigate whether there are specific regions that are potentially 
effective in managing tics and comorbidities in order to better 
predict patient response. In collaboration with the International 
TS DBS Database and Registry, we have assembled the first 
retrospective data set on 123 patients with TS from 13 inter-
national clinic sites that includes structural imaging, stimulation 
settings, and pre-DBS and post-DBS clinical outcomes data. We 
assessed the effects of DBS on TS and OCB severity over time 
and identified any differences across brain targets, comorbidi-
ties and demographics. Patient-specific DBS lead locations and 
VTA were coregistered to a common neuroanatomical space to 
provide the first visualisation of active contacts and regions of 
stimulation across several DBS targets, studies and clinic sites. 
We note that the present data set was limited to mostly open-
label data from multiple clinic sites that were heterogeneous in 
quality and completeness. Therefore, we focused this first study 
on analyses that leverage this unique data set to systematically 
compare how DBS has been delivered across patients with TS in 
an effort to improve our ability to predict therapeutic response 
and generate new hypotheses about potentially effective targets 
for DBS therapy in patients with treatment-refractory TS.
MeThods
Patient cohort
This study included data on a subset of patients from the Inter-
national TS DBS Database and Registry in coordination with 
the International Neuromodulation Registry at the University of 
Utah.18 61 Retrospective data were collected on patients receiving 
bilateral DBS therapy for treatment-refractory TS. Patients were 
selected for DBS therapy based on local evaluations in accor-
dance with published recommendations.62 Quadripolar DBS 
leads were implanted bilaterally in each patient (lead models 
of patients with available data: Medtronic 3387 (n=44), 
Medtronic 3389 (n=21) and NeuroPace DL-330–3.5 (n=5)). 
The data collected during follow-up at each clinic site included 
demographics, comorbidities, brain region(s) targeted with DBS, 
stimulation settings, preoperative and postoperative clinical 
rating scale scores, and preoperative and postoperative MRI 
and/or CT. The primary outcome used in this study was the Yale 
Global Tic Severity Scale (YGTSS) total score.63 The secondary 
outcomes included the YGTSS subscores (motor, phonic and 
impairment) and the Yale-Brown Obsessive Compulsive Scale 
(Y-BOCS) score.64 The main inclusion criteria for patients in this 
study were a preoperative YGTSS total score and a minimum 
of one postoperative YGTSS total score. A total of 110 patients 
were included in the final cohort.
In order to precisely localise the DBS electrodes and perform 
accurate image registration, we enforced the following quality 
control inclusion criteria for the imaging analysis: the patient 
must have both preoperative T1-weighted MRI and postoper-
ative MRI/CT or only postoperative T1-weighted MRI with a 
voxel size of less than 3.0×3.0×3.0 mm, discernible contrast 
between white matter and grey matter structures, and minimal 
motion or image acquisition-related artefacts. There were 70 
patients (148 bilateral leads, 1 unilateral right lead) included in 
the cohort for active contact analysis. Patients implanted in the 
GPi (n=30, 60 bilateral VTA) and patients implanted in the CM 
thalamus (n=33, 64 bilateral VTA, 1 unilateral right VTA) were 
included in the PSA analyses. Patients implanted in the NA/ALIC 
or multiple bilateral targets were excluded from the PSA analyses 
due to small sample sizes.
Patient-specific models
For each patient, we identified the DBS contact locations and 
constructed computational models to estimate the VTA using 
previously described methods.52 Bilateral electrode contacts 
were localised using the lead artefacts in the postoperative CT or 
MRI. Preoperative MRI and postoperative MRI or CT volumes 
were aligned using BRAINSFit rigid registration65 implemented 
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in 3D Slicer (http://www. slicer. org).66 We constructed an 
isotropic finite element model (FEM) of the DBS lead geometry 
and surrounding conductive tissue using SCIRun software (V.5.0, 
SCI Institute, Salt Lake City, Utah). The FEM was used to solve 
for the spatial electric field generated by the stimulation settings. 
The resulting electric field was then applied to multicompart-
ment axon models implemented in NEURON software.67 68 The 
VTA was defined as the volume that encompassed the axons that 
fired action potentials in lockstep with the stimulation pulse. 
Bilateral VTA were generated for each patient using the stimula-
tion parameters recorded at the final follow-up time point.
Coregistration to cohort atlas
An MRI cohort atlas was constructed to serve as a common coor-
dinate space to facilitate cross-patient comparisons of the DBS 
electrode and VTA locations. We implemented a hierarchical 
approach for constructing the atlas to minimise error attributed 
to differences in image acquisition and quality across sites.69 70 
The subset of 58 patients with high-quality preoperative MRI 
(approximately 1 mm3 voxels, high contrast and minimal arte-
facts) was further divided into 5 subgroups of 11–13 patients 
according to clinic site. An atlas was generated using skull-
stripped preoperative MRI for each of the five subgroups using 
the SyN nonlinear image registration method implemented in 
Advanced Normalization Tools (ANTs) software.71 The final 
cohort atlas was generated using the subgroup atlases as the 
input image volumes. For patients whose preoperative MRI were 
not included in the cohort atlas (n=8) and patients with only 
postoperative MRI (n=10), nonlinear image registration using 
SyN in ANTs was used to warp the final MRI cohort atlas to 
each respective patient’s imaging. Using the resulting transfor-
mations, DBS electrode locations and VTA were coregistered 
to the cohort atlas. To visualise detailed segmentations of the 
target nuclei in cohort atlas space, we performed nonlinear 
image registration of the MNI ICBM 2009b Nonlinear Asym-
metric atlas72 73 to our cohort atlas to coregister select atlases 
that were already aligned to the MNI atlas and available from 
the Lead-DBS software.74 The Harvard-Oxford atlas75–78 was 
used to obtain bilateral segmentations of the thalamus and NA/
ALIC. The DBS Intrinsic Template AtLas (DISTAL) atlas79 80 was 
used to obtain bilateral segmentations of the GPi, GPe, CMn-Pf 
complex and Voi nucleus.
Probabilistic stimulation atlases
We generated PSAs in cohort atlas space to compare the brain 
regions stimulated across patients and analyse the relationship 
between stimulation location and clinical outcomes using previ-
ously reported methods.55 56 A 128×128×128 grid was created 
with 0.5 mm3 voxels that encompassed the coregistered VTA 
in cohort atlas space. Voxels of the grid that overlapped with 
each VTA were assigned a value of 1 and all other voxels were 
assigned a value of 0, generating a binary VTA for every patient. 
A voxel-wise sum of the binary VTA was calculated to create a 
map of the number of overlapping VTA at each voxel to visualise 
the commonly stimulated regions. PSAs of the average per cent 
in clinical rating scale scores (YGTSS total and Y-BOCS total 
scores) were created by assigning the voxels in the grid with the 
respective per cent change in clinical rating scale and averaging 
across all VTA at each voxel. A threshold was applied to visualise 
voxels with data from at least three patients. Finally, patients 
were grouped into responders (≥40% reduction in YGTSS total 
score) and nonresponders (<40% reduction in YGTSS total 
score). We chose a response threshold of 40% for two reasons: (1) 
two studies81 82 found that a 25%–35% improvement in YGTSS 
total score was the threshold to detect a clinically meaningful 
change in tic severity, and (2) a 40% reduction in TS symptoms 
is likely to be above any placebo effects, especially in a popula-
tion with such severe and treatment-refractory symptoms. In the 
PSAs, the responders’ VTA, nonresponders’ VTA and the regions 
where they overlapped were visualised. We further characterised 
the overlap regions by mapping the ratio of nonresponder VTA 
and responder VTA at each voxel. PSAs were visualised as scalar 
overlays without interpolation using 3D Slicer software (http://
www. slicer. org).66
statistical analysis
Cohort characteristics were summarised using descriptive statis-
tics. To assess whether TS severity changed over time compared 
with baseline, multilevel linear mixed effects regression models 
were implemented. Random intercepts were included to allow 
for correlation among repeat outcome measures within patients 
and random effects for patients nested within clinic sites. We 
tested for a random slope for time in the model of YGTSS total 
scores, but it did not significantly improve the fit (p=0.395) and 
therefore was not included in the models. Variations by patients 
and clinic site were summarised using intraclass coefficients. 
Models were first conducted without covariate adjustment, 
followed by full multivariable models including age, sex and 
OCB status. Patients with missing data for age, sex or OCB status 
were excluded from the full multivariable models. The other 
comorbidities (attention deficit disorder, depression and anxiety) 
were not included due to sample sizes. We first tested for differ-
ences in YGTSS total scores over time and then tested for brain 
target by time interactions. Similar models were performed for 
all secondary outcomes (YGTSS subscores and Y-BOCS scores). 
Because OCB was strongly associated with Y-BOCS scores, OCB 
status was not included in the Y-BOCS models. Only patients 
implanted in the amGPi or CM thalamus were included in the 
secondary outcome models due to small sample sizes in the other 
targets. Time was modelled continuously but shown descriptively 
in 6-month to 12-month intervals. It was noted that YGTSS and 
Y-BOCS scores were inversely associated with severity, meaning 
that higher scores signified more severe symptoms.
A Kaplan-Meier analysis was performed to estimate the 
median time to reach clinical response to DBS. Stepwise cumula-
tive probability curves and 95% CIs were calculated to estimate 
the median time (in months) to response. Log-rank tests were 
used to compare response curves for patients implanted in the 
CM thalamus versus the GPi, patients with TS and OCB versus 
patients without OCB, and patients grouped by age at implan-
tation (<21 years, 21–30 years, 31–40 years and >40 years). 
Two-sided p values less than 0.05 were considered statistically 
significant. All statistical analyses were performed using SAS 
V.9.4.
resulTs
Patient cohort
Retrospective data were collected from 123 patients from 13 
different institutions across North America (39 patients), Europe 
(63 patients) and Asia (21 patients). Clinical data were available 
for a subset of 110 patients to be included in the statistical anal-
ysis of long-term clinical outcomes (table 1).
The mean (SD, range) follow-up duration was 33.7 (24.1, 
1.0–120.0) months, and the mean (SD, range) number of 
follow-up time points per patient was 3.8 (1.2, 1–9). Stimulation 
settings recorded at the final follow-up time point are reported 
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Table 1 Baseline characteristics of patients with Tourette syndrome 
receiving deep brain stimulation therapy
Characteristics
Patients, number/
total number with 
data (%)
Sex
  Male 76/110 (69.1%)
  Female 34/110 (30.9%)
Age, mean (SD, range) years
  At onset (n=59 patients) 8.0 (3.8, 2.0–20.0)
  At diagnosis (n=17 patients) 10.8 (5.6, 3.0–23.0)
  At surgery (n=110 patients) 30.1 (10.9, 14.0–61.0)
Comorbidities
  Obsessive–compulsive behaviour 56/80 (70.0%)
  Depression 28/43 (65.1%)
  Anxiety 23/39 (59.0%)
  Attention deficit disorder (or attention deficit 
hyperactivity disorder)
8/24 (33.3%)
Clinical rating scale scores, mean (SD)
  Yale Global Tic Severity Scale (YGTSS) total score (n=110) 69.4 (22.6)
  YGTSS motor score (n=61) 22.6 (5.4)
  YGTSS phonic score (n=61) 20.1 (8.2)
  YGTSS impairment score (n=48) 40.7 (13.0)
  Yale-Brown Obsessive Compulsive Scale total score 
(n=68)
18.5 (11.8)
Target brain region (bilateral)
  Centromedial (CM) thalamus 51/110 (46.4%)
  Anterior globus pallidus internus (GPi) 27/110 (24.5%)
  Posterior GPi 20/110 (18.2%)
  Nucleus accumbens area/anterior limb of internal capsule 
(NA/ALIC)
4/110 (3.6%)
  CM thalamus and anterior GPi 3/110 (2.7%)
  CM thalamus and NA/ALIC 5/110 (4.5%)
in online supplementary table 1. Across all targets, 76 patients 
(69.1%) received monopolar or multiple monopolar stimulation, 
32 patients (29.1%) received bipolar stimulation and 2 patients 
(1.8%) received monopolar stimulation in one hemisphere and 
bipolar in the other. There were 73 patients (66.4%) programmed 
with identical bilateral stimulation settings (frequency, pulse 
width and voltage) and symmetric contact configurations, and 
10 patients (9.1%) were programmed with the identical bilateral 
stimulation settings but asymmetric contact configurations.
Post-dbs clinical outcomes over time
YGTSS total scores, YGTSS subscores and Y-BOCS total scores 
over time are shown grouped by target in figure 1. The mean 
(SD) improvement in YGTSS total scores at the final follow-up 
time point compared with baseline was 46.7% (29.7) and 
21.1% (52.9) for Y-BOCS total scores across all patients. The 
multivariable linear mixed effects model showed that YGTSS 
total scores significantly decreased over time (β=−0.6, 95% 
CI (−0.8 to –0.4), p<0.0001). Baseline YGTSS total scores 
did not differ across brain targets (p=0.088). There were no 
significant differences in YGTSS total scores over time across 
brain targets (p=0.671) and scores did not vary by gender 
(p=0.069). Patients with OCB had significantly higher YGTSS 
total scores than patients without OCB (β=17.1, 95% CI (7.2 
to 27.0), p=0.0008). Patients implanted at an older age had 
significantly lower YGTSS total scores (β=−0.6, 95% CI (−1.0 
to –0.2), p=0.006). Intraclass coefficients indicated that 50.8% 
of the variations in YGTSS total scores were due to variations by 
patients and 3.8% were due to variations by clinic site. Statis-
tical models performed for the secondary outcomes showed that 
YGTSS subscores also significantly decreased over time (motor: 
β=−0.2, 95% CI (−0.2 to −0.1), p<0.0001; phonic: β=−0.1, 
95% CI (−0.2 to –0.1), p=0.0001; impairment: β=−0.3, 95% 
CI (−0.5 to –0.1), p=0.0008), but there were no significant 
differences in patients implanted in the amGPi compared with 
patients implanted in the CM thalamus (motor: p=0.6; phonic: 
p=0.56; impairment: p=0.72). Patients with OCB had signifi-
cantly higher YGTSS motor scores (β=3.8, 95% CI (1.5 to 6.1), 
p=0.001) and YGTSS phonic scores (β=3.6, 95% CI (0.5 to 
6.6), p=0.022) than patients without OCB, but there was no 
statistical difference in YGTSS impairment scores (β=5.1, 95% 
CI (−2.3 to 12.6), p=0.175). Male patients had significantly 
lower YGTSS phonic scores than female patients (p=0.022). 
Y-BOCS total scores also significantly decreased over time 
(β=−0.1, 95% CI (−0.2 to 0.0), p=0.002). There was no signif-
icant difference in Y-BOCS total scores across patients implanted 
in the amGPi compared with patients implanted in the CM thal-
amus (p=0.24).
Cumulative probability curves were generated using Kaplan-
Meier survival analysis to determine the median time to clinical 
response, which was defined as a 40% reduction in YGTSS total 
score (figure 2). The median time to response across all patients 
in the cohort was 13 months (95% CI 12 to 24), with 69.1% 
of patients reaching response criteria by 60 months (figure 2A). 
The median time to response for patients implanted in the GPi 
(18 months, 95% CI 12 to 24) was longer than the median time 
for patients implanted in the CM thalamus (12 months, 95% 
CI 8 to 14), but the difference was not significant (χ2=0.042, 
p=0.84) (figure 2B). There was no significant difference in the 
median time to response for patients with TS with OCB (24 
months, 95% CI 12 to 24) compared with those without OCB 
(11 months, 95% CI 6 to 15) (χ2=2.87, p=0.09) (figure 2C). 
The cumulative probability curves were compared for patients 
grouped by age at implantation (<21 years, 21–30 years, 31–40 
years and >40 years) (figure 2D). The median response time of 
the youngest population (<21 years) was 12 months (95% CI 8 
to 18), which was the same as the oldest population (>40 years) 
(95% CI 6 to 24). There was no significant difference in response 
curves among any of the age groups (χ2=6.65, p=0.084).
Variability of active contact locations
Bilateral active DBS contact locations for 70 patients recorded 
at their final follow-up time point were mapped into the cohort 
atlas space. The active contact locations were visualised relative 
to segmentations of the targeted nuclei (figure 3A) and reported 
in mean (SD) millimetres relative to the mid-commissural point of 
the cohort atlas brain (figure 3B). The targets listed in figure 3B 
represent the general target regions reported by the clinic site and 
do not necessarily indicate the anatomical structures in which the 
contacts were located. In general, active contacts were located near 
the intended targeted nuclei. In the targets with more than three 
patients (amGPi, pvGPi and CM thalamus), the highest SD was in 
the axial direction, which was likely attributed to which contact(s) 
on the DBS lead were selected. Among patients implanted in the 
amGPi, there was higher variability in active contact locations in 
the sagittal axis in the right hemisphere (SD=2.5 mm) than the left 
(SD=1.2 mm). The CM thalamus contacts in patients implanted 
bilaterally in both the CM thalamus and the GPi were located more 
posterior than the CM thalamus contacts in patients implanted 
bilaterally in both the CM thalamus and NA/ALIC. The GPi 
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Figure 1 Tic severity and obsessive–compulsive behaviour over time. (a) YGTss total scores over time grouped by DBs target. (B–D) YGTss subscores 
(motor, phonic and impairment) over time grouped by DBs target. (e) Y-BOcs total scores over time grouped by DBs target. YGTss subscores and Y-BOcs 
scores were collected for only a subset of the targets. The number of patients in each group is annotated above each boxplot and is coloured according to 
the legend. aLIc, anterior limb of the internal capsule; amGpi, anteromedial globus pallidus internus; DBs, deep brain stimulation; cM, centromedial; Na, 
nucleus accumbens; pvGpi, posteroventral globus pallidus internus; Y-BOcs, Yale-Brown Obsessive compulsive scale; YGTss, Yale Global Tic severity scale.
contacts in patients implanted bilaterally in both the CM thalamus 
and the GPi were located in either the amGPi (n=2) or the pvGPi 
(n=1).
Probabilistic stimulation atlases
We generated a series of PSAs using the VTA and per cent change 
in clinical outcome scores in 30 GPi DBS patients (figure 4). 
Expanded panel views of these PSAs are shown in online supple-
mentary figures 1-5. First, we found that the most commonly 
stimulated region was located within the amGPi and the regions 
inferior to the pallidum (figure 4A). The total area stimulated 
across patients extended laterally into the regions in GPe and 
medially into the internal capsule. There were multiple disjointed 
regions with lower average per cent tic improvement and higher 
average per cent improvement spanning the GPi, the GPe and the 
surrounding areas (figure 4B). A region located medial to the right 
GPi had the highest mean per cent improvement in the PSA, but 
the region encompassed VTA of only three patients. We also visu-
alised the VTA of nonresponders (n=13 patients) and responders 
(n=17 patients) and the region where they overlapped (figure 4C). 
The region of overlap encompassed 51.0% of the total volume 
of stimulation. The regions where only nonresponders (11.2% 
of the total volume) and only responders (37.8% of the total 
volume) were stimulated included only three or fewer VTA. We 
further characterised the region of overlap by mapping the ratio 
of nonresponder VTA and responder VTA (online supplementary 
figure 5). In the PSA of mean per cent improvement of the Y-BOCS 
scores (figure 4D), we observed a gradient-like trend in mean per 
cent improvement in Y-BOCS total score from greater average 
improvement in the more superior regions to least improvement 
or worsening of symptoms in the regions inferior to the GPi. The 
VTA of patients who experienced less than 25% improvement of 
the Y-BOCS scores (n=4) or worsening of OCB symptoms (n=4) 
overlapped with a region located inferior to the GPi. Five of these 
patients’ VTA also overlapped with the GPi and/or the GPe. In 
contrast, the VTA of 12 patients who experienced greater than 
25% improvement of the Y-BOCS score overlapped with the GPi, 
GPe or regions located superior or medial to the pallidum, but only 
one patient’s bilateral VTA extended into the regions below the 
GPi.
A series of PSAs were also generated using the VTA of the 33 
patients implanted in the CM thalamus (figure 5). Expanded 
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Figure 2 Median time to response across the Ts DBs cohort and subgroups. (a) cumulative probability of response for all patients in the cohort (N=110). 
(B) cumulative probability of response for patients implanted in the Gpi and cM thalamus. (c) cumulative probability of response in patients with Ts and 
OcB and patients with Ts only. (D) cumulative probability of response in patients grouped by age at DBs implantation. The shaded regions are 95% cIs. 
The numbers of patients and the median times to response (in months) are listed in the legends. cM, centromedial; DBs, deep brain stimulation; Gpi, globus 
pallidus internus; OcB, obsessive–compulsive behaviour; Ts, Tourette syndrome; YGTss, Yale Global Tic severity scale.
panel views of these PSAs are shown in online supplementary 
figures 6-10. The region with the greatest number of overlapping 
VTA was located at the intersection of the CMn-Pf complex-Voi 
(figure 5A). Regions that produced higher mean improvement 
were intermixed with regions that produced lower mean improve-
ment across patients (figure 5B). The VTA of responders (n=17 
patients), nonresponders (n=16 patients) and the regions where 
they overlapped are visualised in figure 5C. The region of overlap 
was 56.7% of the total volume of stimulation. Regions where 
only nonresponders and responders were stimulated encompassed 
18.7% and 24.6%, respectively, but these regions comprised only 
three or fewer VTA. We also created a PSA of the ratio of nonre-
sponder VTA and responder VTA in the overlap region (online 
supplementary figure 10). The regions in which there were more 
nonresponder VTA than responder VTA were located anterior, 
lateral and inferior to the CMn-Pf complex and within the Voi. 
The mean per cent improvement in Y-BOCS total score at the final 
follow-up time point for 17 CM thalamus DBS patients was over-
laid in the cohort atlas space (figure 5D). In the left hemisphere, 
there was a gradient-like trend with lower per cent improvement 
located in the inferior regions of the CMn-Pf complex and greater 
per cent improvement located in more superior regions between 
the CMn-Pf complex and Voi nucleus. However, this pattern 
was not symmetric; one patient with a unilateral lead implanted 
in the right hemisphere experienced a 125% worsening of OCB 
symptoms.
dIsCussIoN
effects of dbs for Ts over time
The long-term clinical outcomes analysis showed that the 
YGTSS motor, phonic, impairment and total scores and Y-BOCS 
total scores significantly improved over time in response to DBS, 
indicating that DBS may be effective in reducing tic severity and 
OCB (figure 1). These findings are consistent with the results 
previously reported by meta-analyses and the International TS 
DBS Database and Registry, from which the present data set 
includes a subset of patients.18 51 The data in this study were 
drawn from mostly open-label studies that were performed at 
multiple sites that differed in surgical techniques and treatment 
approaches. This may have biased the results, but our statistical 
analysis showed that only 3.8% of the variability in YGTSS 
total scores was attributed to differences across sites. Because 
the data were drawn from mostly open-label studies, it is also 
possible that the results of the clinical outcomes analysis and 
PSAs were influenced by placebo effects. However, randomised 
controlled trials have reported that tics significantly improved in 
patients receiving active stimulation, and there were no signifi-
cant changes in symptoms in response to sham stimulation.22 34 39 
Across these trials, the mean or median change in YGTSS total 
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Figure 3 Variability of bilateral active DBs contact locations in the cohort atlas space. (a) Three-dimensional superior view of the locations of the 
active contacts in the cohort atlas space for n=70 patients relative to nuclei segmentations. each sphere represents an active DBs contact and is coloured 
by intended DBs target region as listed in the legend in (B). (B) sagittal (x), coronal (y) and axial (z) coordinates in mean (sD) mm relative to the mid-
commissural point of the cohort atlas. DBs, deep brain stimulation.
scores in response to sham stimulation ranged only from −7.2 
points (improvement)22 to +0.9 points (worsening).39 This indi-
cates that the placebo response to stimulation is likely to be 
lesser in magnitude than the therapeutic response to active stim-
ulation, and therefore the observed improvements in tics are not 
likely attributed to placebo effects alone. Although our results 
indicate that DBS may be effective for TS, additional randomised 
controlled trials in large cohorts are needed to definitively 
conclude that DBS is effective in reducing tics and comorbidities 
in patients with TS.
We observed that the median time was 13 months for 
patients to reach a 40% reduction in tic severity across all 
targets (figure 2). We varied the criteria for response from 40% 
improvement to other thresholds, and the time to response 
remained on the order of multiple months. One limitation of 
this analysis was that this data set included follow-up time points 
at the resolution of months, so a detailed analysis at smaller 
time intervals was not possible. Our results indicate that clini-
cians may need to be more patient with TS DBS compared with 
other indications, and detailed data of any stimulation setting 
changes should be recorded to facilitate careful reconstruction 
of the acute and long-term effects of stimulation. Other studies 
have reported that the effects of TS DBS are often not immediate 
and wash-in/washout times vary.22 39 48 83 However, an important 
dispute is whether the observed delayed response to DBS was 
due to TS symptoms requiring more time to respond to DBS or 
if it was due to better titration of stimulation settings over time. 
The delayed response also may be attributed, in part, to sponta-
neous fluctuations in tics that were independent from the clinical 
response to DBS or any placebo effects.
The mechanisms of the onset of the effects of TS DBS remain 
unclear, but studies of DBS for other psychiatric disorders, such 
as OCD and treatment-resistant depression, have also reported 
that the time to see a significant effect is often on the order of 
months.49 84 85 The therapeutic response to DBS for depression 
or OCD is thought to be mediated by neuroplasticity that leads 
to local and/or network activity that restores normal function to 
pathological neurocircuitry.84–87 It has also been reported that the 
effects of DBS for dystonia develop over the course of months, 
with some patients experiencing improvements after 3–6 months 
of stimulation in the GPi, although the underlying mechanisms 
remain unclear.88 89 Acute effects of DBS for TS have been inves-
tigated in nonhuman primate models90 and through intraopera-
tive microelectrode and local field potential (LFP) recordings in 
humans,91–93 but it is unclear whether changes in neuroplasticity 
underlie the long-term therapeutic effects of DBS in TS. Chronic 
LFP recordings in one patient with TS suggested that DBS does 
not induce changes in LFP oscillatory activity over the course 
of 12 months,94 but further research is needed to elucidate the 
long-term mechanisms of DBS for TS.
Comparison of clinical outcomes across brain targets
We found no significant differences in YGTSS scores or Y-BOCS 
scores over time among patients implanted in the CM thalamus 
versus amGPi, which suggests that the CM thalamus and amGPi 
both may be effective in improving TS symptoms and OCB. These 
results are in agreement with the results reported by meta-anal-
yses and the International TS DBS Database and Registry.18 51 
The finding that multiple nuclei may be effective targets for DBS 
has also been shown in other indications; for example, both the 
subthalamic nucleus and GPi have been shown to be effective 
DBS targets for Parkinson’s disease.95 There were also no signif-
icant differences in the median time to response among patients 
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Figure 4 psas of clinical outcomes in Gpi DBs patients. (a) psa of the proportion of the total number of patients stimulated at each voxel. The region 
with the greatest number of overlapping VTa across Gpi DBs patients was located within the amGpi and the regions inferior of the amGpi. (B) psa of the 
mean per cent improvement in YGTss total score. (c) Regions stimulated in nonresponders, responders and the regions where they overlapped. There was 
substantial overlap of effective regions and regions that were associated with little to no therapeutic benefit. (D) psa of the mean per cent improvement in 
the Y-BOcs total score showed that the VTa of patients who did not reach a 25% improvement extended below the Gpi. The VTa of patients who reached 
a >25% improvement were located within the pallidum and/or medial or superior to the pallidum and did not extend below the Gpi. segmentation outlines 
of nuclei are overlaid for reference (Gpi, yellow; Gpe, white). For axial and sagittal views, see online supplementary figures 1-4. amGpi, anteromedial globus 
pallidus internus; DBs, deep brain stimulation; Gpe, globus pallidus externus; Gpi, globus pallidus internus; psa, probabilistic stimulation atlas.
implanted in the CM thalamus versus GPi. It has been hypoth-
esised that because the CM thalamus and amGPi are thought 
to be connected within the same CSTC network,7 96 stimu-
lating either target may modulate pathological CSTC activity 
to reduce TS and comorbidities.31 97 98 A recent study showed 
that there is oscillatory coupling of the CM thalamus and GPi in 
the theta and beta frequency ranges, indicating a possible func-
tional link between the two structures and their involvement in 
TS pathology.99 Several interconnected regions have also been 
implicated in TS as well as OCB, including thalamic regions, 
pallidum, other basal ganglia nuclei and cortical regions.100 101
Double-blind, sham-controlled studies on small cohorts of 
patients with TS implanted with DBS leads in both the CM thal-
amus and GPi (amGPi or pvGPi) have reported that the ther-
apeutic effects did not greatly differ across targets; however, 
GPi DBS yielded better tic improvement in some patients.20 38 
Although our analysis of the cohort data revealed no statistical 
difference across targets, there may be one target that is more 
effective for specific patients. It is still unclear which factors are 
important for determining which target is suited for any given 
patient; some have speculated that in select cases, DBS of the 
CM thalamic regions was not sufficient for alleviating severe 
OCB and targeting the amGPi may be more effective.37 Future 
studies that include patients implanted with bilateral leads in 
both the CM thalamus and the GPi should be carefully designed 
such that the effects of the two targets can be directly compared 
within a single patient.
Variability of active contact locations
We present the first visualisation of bilateral active contact loca-
tions across multiple patients with TS, studies, clinic sites and 
DBS targets (figure 3). The visualisation shows that active contact 
locations are variable across all of the intended target nuclei. 
This variability highlights the importance that future studies 
visualise where the electrodes were implanted relative to the 
surrounding anatomy in each patient to facilitate future compar-
isons. Open-source tools, such as Lead-DBS,74 are available to 
perform lead localisation in individual subjects. We speculate 
that the variability in contact locations may be attributed, in part, 
to the fact that several groups’ surgical targets differed slightly in 
location within nuclei. A good example of this is evident in the 
four different anatomical regions that have been targeted within 
the CM thalamus.19 33 37 38 Another potential source of vari-
ability is that not all patients were implanted with the same lead 
model, and contacts at different positions on the lead were often 
selected. We also observed some asymmetry in the contact loca-
tions across hemispheres. One hypothesis is that with bilateral 
implantation, brain shift occurs after implanting the first lead, 
and therefore the second lead may be slightly displaced despite 
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Figure 5 psas of clinical outcomes in cM thalamus DBs patients. (a) psa of the proportion of the total number of patients stimulated at each voxel. The 
region with the greatest number of overlapping VTa across the cM thalamus DBs patients was located at the intersection of the cMn-pf complex-Voi. (B) 
psa of the mean per cent improvement in YGTss total score. (c) Regions stimulated in nonresponders, responders and the regions where they overlapped. 
There were regions associated with improvement and overlapping regions associated with little to no therapeutic benefit. (D) psa of the mean per cent 
improvement in the Y-BOcs total score. segmentation outlines of the nuclei are overlaid for reference (thalamus, white; cM nucleus, light blue; pF complex, 
dark green; Voi, yellow-green). For axial and sagittal views, see online supplementary figures 6-9. cM, centromedial; cMn-pf, centromedian nucleus-
parafascicular; DBs, deep brain stimulation; psas, probabilistic stimulation atlases; Voi, ventro-oralis internus.
accurate preoperative planning.102–104 There also may be slight 
registration errors in warping patient imaging to atlas space, and 
we were especially cognisant of this. Lead locations relative to 
structural anatomy in atlas space were carefully compared with 
those in native patient imaging space. Patients with inaccurate 
registrations were excluded from the analysis (n=8), but slight 
errors may still have been present.
Probabilistic stimulation atlases
Our results indicate that stimulation location relative to struc-
tural anatomy alone did not predict the effect of DBS on tic 
severity. There were multiple regions within the CM thalamus 
and GPi that substantially improved tics for some patients but 
induced minimal effects for others, and there were relatively 
large regions of overlap of responders and nonresponders in 
both the CM thalamus and the GPi. We varied the criteria for 
response from 40% to other thresholds, but this did not substan-
tially change the responder/nonresponder PSAs for either the 
CM thalamus or GPi. We could not draw any definitive conclu-
sions about specific anatomical regions to target or avoid for 
beneficial effects on tics. Previous studies of lesion therapy and 
DBS for Parkinson’s disease have also reported that there was 
substantial overlap in lesions and active contact locations that 
improved symptoms in some patients and not in others.105 106 
This overlap suggests that the therapeutic effects of DBS in 
some indications are likely attributed to several complex factors 
beyond only the anatomical region of stimulation. However, we 
found that patients stimulated within the pallidum or medial or 
superior to the pallidum experienced beneficial improvement 
in the Y-BOCS total score, and patients stimulated in regions 
directly inferior to GPi experienced little to no improvement 
(figure 4). Although it was in only 20 patients, the observed trend 
suggests that stimulating regions inferior to the pallidum may be 
less effective in reducing OCB. This trend could potentially be 
tested by altering contact configurations in patients whose OCB 
is unresponsive to reduce the stimulation of regions inferior to 
the GPi. Because the data for the PSA analyses were mostly from 
open-label studies, it is unclear if placebo effects or natural fluc-
tuations in tics may have affected the results. Therefore we are 
cautious to draw definitive conclusions about specific anatomical 
regions to target or avoid for improving tics or comorbidities.
One limitation of PSAs is that there is often a confined 
spatial distribution of electrode locations and VTA.57 58 This is 
a product of the location of the electrode and the stimulation 
parameters for each patient, as well as the spatial clustering of 
leads near the target. Many VTA were overlapping within the 
intended targets in the GPi and CM thalamus, and relatively few 
were located in the surrounding regions. This overlap was espe-
cially prevalent in the GPi, where contact locations were clus-
tered together and some of the stimulation settings resulted in 
larger VTA, which in turn resulted in larger regions of overlap 
among patients (figure 4). Detailed statistical models used in 
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other PSA studies could be applied to test whether any observed 
trends were statistically significant.55 57 This approach has been 
applied in a smaller cohort of TS DBS patients implanted in the 
amGPi, but no regions were found to be statistically significant 
after correcting for multiple comparisons.107
Stimulation parameters also likely play a role in mediating 
both the acute and long-term response to DBS. We observed 
variability in frequency, pulse width, voltages and contact config-
urations among patients and targets (online supplementary table 
1). Controlled trials that compare pulse widths or frequencies 
are an important next step to determine the efficacy of different 
stimulation parameters. Another limitation of this study was 
that the regions associated with stimulation-induced side effects 
could not be assessed because the reported side effects were not 
linked to a specific set of stimulation parameters. In our PSAs, we 
used data from only the final time point per patient to compare 
VTA across the greatest number of patients. However, using 
data from a single time point for each patient provides only a 
‘snapshot’ in time of the patient’s response to one set of stimu-
lation parameters. Given the complex clinical time course of TS 
symptoms and in light of our Kaplan-Meier results, time is an 
important variable to be considered in future studies. Incorpo-
rating multiple VTA from several time points per patient could 
be a way to capture the variability in outcomes over time and 
investigate the relationship between stimulation regions and the 
long-term effects of DBS.
The data set used to generate the PSAs was limited to only 
patients with imaging that met the strict quality control criteria. 
We collected structural imaging on 123 patients, but 53 patients 
(43%) were excluded from the imaging-based analysis, often due 
to low-resolution postoperative imaging (n=24 patients). Addi-
tionally, several patients’ preoperative imaging was excluded 
due to low resolution and/or poor structural contrast. Acquiring 
high-quality preoperative and postoperative imaging is the first 
step in precisely localising DBS electrodes and creating accu-
rate patient-specific models. Preoperative T1-weighted MRI 
should be acquired with at least 1.0 mm isotropic voxels, and 
the magnetization-prepared rapid acquisition with gradient 
echo (MP2RAGE) sequence on a 3T scanner produces high 
signal-to-noise ratios for accurate registration and segmentation 
protocols.108 For accurate localisation of the electrode contacts, 
postoperative imaging resolution of 1.0×1.0×1.0 mm or less is 
required because larger voxel sizes prevent clear visualisation of 
the individual electrodes.109 Postoperative CT is preferred over 
MRI because the distortion artefact induced by the electrode is 
reduced in CT imaging, which allows for more precise electrode 
localisation.110 111
Improving future analyses of dbs for Ts
Based on our results and given the complexity of TS and its 
associated comorbidities, we postulate that it is unlikely there 
is a single most effective neuroanatomical region that improves 
tics and comorbidities across patients with TS. We propose that 
future studies should incorporate multiple types of data beyond 
structural imaging and be designed in such a way to learn as 
much as possible from each patient in order to guide future DBS 
therapy for TS. First, the power of this study was limited by the 
fact that most of the data were open-label. Future efforts should 
be directed towards obtaining data that are properly controlled 
and collected by blinded raters, which can be facilitated by 
using video-based assessments such as the Rush Video-Based Tic 
Rating Scale.16 112 113
High-quality preoperative imaging of multiple modalities 
(T1-weighted MRI, diffusion-weighted imaging (DWI) and rest-
ing-state functional MRI) should be acquired in each patient. 
Multiple imaging modalities are important for creating detailed 
patient-specific models that incorporate connectivity data in 
order to study how fibre pathways and functional networks are 
being modulated in a single patient with TS and how this may 
contribute to response. TS and its associated comorbidities are 
highly heterogeneous from patient to patient. Detailed patient 
characteristics, such as symptom profiles (tic types and comorbid 
behaviours), medications, time course of symptoms and severity 
of comorbidities, need to be collected in order to study their role 
in the response to DBS and to further characterise the pathology 
that contributes to different symptoms.114 115 Patient-specific 
clinical characteristics combined with high-quality multimodal 
preoperative imaging would give important insight into how 
differences in connectivity may affect response to DBS. This 
could lead to better stratification of patients into subtypes that 
could guide future treatment strategies. It would be immensely 
powerful to be able to select stimulation targets for individual 
patients based on the combination of their TS and comorbidity 
symptoms, structural neuroanatomy and functional connec-
tivity. The present data set will continue to grow alongside the 
International TS DBS Database and Registry and will serve as an 
important resource for future centres to compare potential TS 
DBS candidates’ profiles against the predicted response rates and 
the reported efficacy of different DBS targets.
There are also emerging technologies that could be leveraged 
to improve DBS for TS. First, tics are paroxysmal, which means 
that closed-loop paradigms could be used as a way to address 
the underlying pathology of TS by triggering or adapting stimu-
lation in response to pathological neural activity.116–119 Prelimi-
nary results showed that closed-loop DBS is effective in reducing 
tics.117 Additionally, closed-loop systems provide the opportunity 
to simultaneously record tic-related neurophysiological activity 
within target nuclei and identify stimulation parameters that 
prevent tics. Another potential avenue for improving DBS for TS 
is the use of novel directional leads to steer stimulation towards 
certain nuclei and away from others (eg, CMn-Pf complex vs 
Voi) to test the contributions of different nuclei to the observed 
response.120 Directional DBS leads could be useful for further 
interrogating the effects of stimulating specific CM thalamic 
nuclei or subregions of the pallidum and perform PSA analyses 
with higher spatial specificity than the PSAs in this study.
CoNClusIoNs
The present study was the first to combine structural imaging, 
patient-specific computational models and clinical outcomes of 
patients with TS receiving DBS therapy into a common atlas 
space to make inferences about how stimulation location affects 
tic severity and OCB. We provide the first visualisation of active 
contact locations and stimulated brain regions across multiple 
patients, targets and clinic sites. The PSAs in the CM thalamus 
and GPi showed multiple intermixed and overlapping regions 
associated with substantial and/or ineffective tic reduction. We 
believe that these findings may be attributed to relatively consis-
tent lead placement and stimulation settings; the regions where 
the greatest number of patients were stimulated were located 
near the most commonly reported surgical targets in the CM 
thalamus and amGPi. The PSA of OCB improvement showed a 
gradient-like trend that suggests regions just inferior to the GPi 
may be less effective in reducing OCB as regions within the pall-
idum or medial or superior to the GPi. Our results collectively 
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indicate that DBS may be an effective therapy for select cases 
of treatment-refractory TS, but targeting based on structural 
anatomy alone may not be sufficient to achieve therapeutic 
benefit in every future patient. Future directions for TS DBS 
should be towards increasing our predictive power to be able to 
integrate symptom profiles, neuroanatomy, functional connec-
tivity, fibre pathway and pathological neural activity in an effort 
to choose targets and stimulation paradigms that most effec-
tively reduce tics and comorbidities on a patient-specific basis. 
As a next step towards this goal, we plan to integrate functional 
connectivity and fibre tracts into the PSAs to provide insight on 
the network-level effects of TS DBS, identify potential novel 
targets that improve tics and OCB, and advance our ability to 
predict clinical outcomes.
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